-+ 0.00%
-+ 0.00%
-+ 0.00%

Radiopharm Theranostics doses first patient in Phase 1 RAD 402 trial for advanced prostate cancer; data from first two dose levels expected in 2H 2026

Reuters·03/27/2026 11:03:21

Please log in to view news